ITOS Stock Overview
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
iTeos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.24 |
| 52 Week High | US$23.00 |
| 52 Week Low | US$11.34 |
| Beta | 1.2 |
| 1 Month Change | 7.09% |
| 3 Month Change | -9.93% |
| 1 Year Change | -37.30% |
| 3 Year Change | -48.00% |
| 5 Year Change | n/a |
| Change since IPO | -35.75% |
Recent News & Updates
Recent updates
Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%
May 13
Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding
Mar 21The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically
Aug 12iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04
Aug 10iTeos Therapeutics: Too Many Unknowns
Jul 27News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts
May 11Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic
Nov 25We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth
Aug 24iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share
Aug 15GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler
Jun 15We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth
Feb 07Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?
Dec 16
iTeos Therapeutics EPS misses by $0.11
Nov 12Shareholder Returns
| ITOS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | -0.5% | -1.5% |
| 1Y | -37.3% | 10.8% | 13.8% |
Return vs Industry: ITOS underperformed the US Biotechs industry which returned 8.8% over the past year.
Return vs Market: ITOS underperformed the US Market which returned 12.9% over the past year.
Price Volatility
| ITOS volatility | |
|---|---|
| ITOS Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in US Market | 14.3% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: ITOS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ITOS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 125 | Michel Detheux | https://www.iteostherapeutics.com |
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company’s product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
iTeos Therapeutics, Inc. Fundamentals Summary
| ITOS fundamental statistics | |
|---|---|
| Market Cap | US$437.97m |
| Earnings (TTM) | -US$28.41m |
| Revenue (TTM) | US$85.99m |
5.1x
P/S Ratio-15.4x
P/E RatioIs ITOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITOS income statement (TTM) | |
|---|---|
| Revenue | US$85.99m |
| Cost of Revenue | US$0 |
| Gross Profit | US$85.99m |
| Other Expenses | US$114.39m |
| Earnings | -US$28.41m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | 100.00% |
| Net Profit Margin | -33.04% |
| Debt/Equity Ratio | 0% |
How did ITOS perform over the long term?
See historical performance and comparison